Tactile Systems reports 21% revenue surge and stronger market share in 2025
Tactile Systems reports 21% revenue surge and stronger market share in 2025
Tactile Systems reports 21% revenue surge and stronger market share in 2025
Tactile Systems Technology, Inc. (TCMD) has reported strong financial results for 2025, with significant growth in revenue and profitability. The company's quarterly earnings for Q4 2025 showed a 21% jump in total revenue, alongside improved margins and stock market share gains in key product areas.
The company's total revenue for Q4 2025 reached $103.6 million, a 21% increase from the same period in 2024. For the full year, revenue climbed 12% to $329.5 million. Gross margin also improved, rising to 78% in Q4 2025 compared to 75% a year earlier.
Profitability saw a boost as well. Net income for Q4 2025 was $10.6 million, up from $9.7 million in Q4 2024. The full-year net income for 2025 reached $19.1 million, an increase from $17.0 million in 2024. Adjusted EBITDA followed a similar trend, with Q4 2025 figures at $22.9 million (up from $16.2 million) and the full-year total hitting $44.8 million (compared to $37.1 million in 2024).
The company's stock market position strengthened following the 2024 publication of clinical data in the Journal of the Sciences and Specialties of the Head and Neck. By Q4 2025, Tactile Medical held a 28% share of the U.S. airway clearance market, up from 19% in 2023. This growth came at the expense of competitors like Hillrom, whose share fell from 25% to 22%, while Aerobix remained stable at 15%. The company attributed its success to superior efficacy in lymphedema and respiratory therapy.
Looking ahead, TCMD forecasts full-year 2026 revenue between $357 million and $365 million, representing growth of 8% to 11%. Adjusted EBITDA for 2026 is expected to range from $49 million to $51 million. The company ended 2025 with $83.4 million in cash, down from $94.4 million at the close of 2024.
Tactile Systems Technology's 2025 results highlight steady revenue growth, improved profitability, and a stronger stock market position in airway clearance products. With optimistic projections for 2026, the company appears poised for continued expansion in its core therapy segments.
Taiwan battles early flu surge and rising dengue fever cases ahead of holidays
A perfect storm of flu and dengue hits Taiwan just as holidays approach. Could crowded gatherings worsen the outbreak?
Johnson & Johnson defies market slump with 15% stock surge in 2024
A pharma giant thrives where others falter. How J&J's billion-dollar drugs and smart spin-offs outperform a volatile market.
India warns Pakistan over Sir Creek with military show of strength
A sacred weapon ritual and a bold warning: India flexes its military muscle as tensions rise over the unresolved Sir Creek border. What happens next?
Guernsey's life-saving cholesterol screening earns national award nomination
A tiny island's bold health initiative is saving lives—and catching national attention. Could this cholesterol screening model reshape care across the UK?